Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study
The Lancet Microbe · 2026-06 · 7 (6) · 101321
DOI: 10.1016/j.lanmic.2025.101321 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Lancet Microbe, 2026-06. Verfasst von Sophia David und 23 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Genomic Pathogen Surveillance, Pandemic Sciences Institute, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: beta-Lactamases, Escherichia coli, Bacterial Proteins, Escherichia coli Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, European Centre for Disease Prevention and Control, Wellcome Trust.
Abstract (Originalsprache)
BACKGROUND: The emergence of carbapenem resistance in Escherichia coli is of major concern due to the high propensity of spread of this species and scarce treatment options. Herein, we examined the occurrence and spread of carbapenem-resistant E coli based on the carbapenem-resistant and/or colistin-resistant Enterobacterales (CCRE) survey performed across European countries in 2019. METHODS: We analysed epidemiological, microbiological, and whole-genome sequencing data of 548 E coli isolates from individual patients from 156 hospitals in 32 European countries over 6 months in 2019. These hospitals collected the first ten successive isolates of carbapenem-resistant or carbapenem-susceptible increased exposure (carbapenem-R/I) Klebsiella pneumoniae species complex or E coli, and carbapenem-susceptible (carbapenem-S) comparator isolates of the same species. Antimicrobial susceptibility testing was performed for 19 antimicrobial agents. Whole-genome sequencing was performed centrally using Illumina technology. Isolates from the CCRE survey were compared with those from the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) study. FINDINGS: Of the 548 E coli isolates, 211 (38·5%) were carbapenem-resistant or susceptible, increased exposure (carbapenem-R/I), and 337 (61·5%) were carbapenem-susceptible (carbapenem-S). Five sequence types (STs) accounted for 96 (45·5%) of 211 carbapenem-R/I isolates: ST131 (27), ST410 (20), ST38 (19), ST167 (16), and ST648 (14). Carbapenemase genes were identified in 182 (86·3%) carbapenem-R/I isolates, a pronounced increase from the 2013-14 EuSCAPE study (36 of 99, 36·4%). The most common genes were blaNDM-5 (62 of 182, 34·1%) and blaOXA-48 (40 of 182, 22·0%). blaNDM-5 carriage increased substantially compared with that in EuSCAPE (two of 99, 2·02%). Phylogenetic analysis showed substantial clonal spread of globally disseminated blaNDM-5-harbouring lineages, with numerous introductions into Europe but minimal onward transmission. INTERPRETATION: High-risk STs of E coli carrying carbapenemase genes are rapidly spreading globally, although our results indicate that, in 2019, most cases in Europe were sporadic. We urge vigilant monitoring, including genomic surveillance, and strengthening of control efforts, to reduce mortality and morbidity associated with the impending rise in carbapenem-R/I E coli cases. FUNDING: European Centre for Disease Prevention and Control and the Centre for Genomic Pathogen Surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Genomic Pathogen Surveillance, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
- European Centre for Disease Prevention and Control, Solna, Sweden. Electronic address: anke.kohlenberg@ecdc.europa.eu.
- European Centre for Disease Prevention and Control, Solna, Sweden.
- Public Health Agency of Sweden, Solna, Sweden.
- Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute, Stockholm, Sweden; Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
- University of Groningen, Groningen, Netherlands.
Förderung
- National Institute for Health and Care Research
- European Centre for Disease Prevention and Control
- Wellcome Trust
Zitieren
APA
David, S., Kohlenberg, A., Yeats, C., Abu-Dahab, K., Albiger, B., Alikhan, N. F., Alm, E., Byfors, S., Couto, N., Diaz Caballero, J., Giske, C. G., Glasner, C., Linkevicius, M., Matuschek, E., Palm, D., Svartström, O., Grundmann, H., Struelens, M. J., Tegmark Wisell, K., …, & EURGen-Net CCRE Survey Working Group (2026). Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study. The Lancet Microbe, 7(6), 101321. https://doi.org/10.1016/j.lanmic.2025.101321
Vancouver
David S, Kohlenberg A, Yeats C, Abu-Dahab K, Albiger B, Alikhan NF, et al. Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study. The Lancet Microbe. 2026;7(6):101321. doi:10.1016/j.lanmic.2025.101321
BibTeX
@article{David2026,
author = {David, Sophia and Kohlenberg, Anke and Yeats, Corin and Abu-Dahab, Khalil and Albiger, Barbara and Alikhan, Nabil-Fareed and Alm, Erik and Byfors, Sara and Couto, Natacha and Diaz Caballero, Julio and Giske, Christian G and Glasner, Corinna and Linkevicius, Marius and Matuschek, Erika and Palm, Daniel and Svartström, Olov and Grundmann, Hajo and Struelens, Marc J and Tegmark Wisell, Karin and Monnet, Dominique L and Fröding, Inga and Aanensen, David M and Brolund, Alma and EURGen-Net CCRE Survey Working Group, EURGen-Net CCRE Survey Working Group},
title = {Emergence of carbapenemase-producing Escherichia coli in acute care hospitals in 32 European countries (the CCRE survey): a prospective, multicentre, cross-sectional, epidemiological, microbiological, and genomic surveillance study},
journal = {The Lancet Microbe},
year = {2026},
volume = {7},
number = {6},
pages = {101321},
doi = {10.1016/j.lanmic.2025.101321}
}
EUVIMED